223 related articles for article (PubMed ID: 12369856)
1. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
Seymour L
Curr Pharm Des; 2002; 8(25):2279-84. PubMed ID: 12369856
[TBL] [Abstract][Full Text] [Related]
2. Development of target-based antineoplastic agents.
Stadler WM; Ratain MJ
Invest New Drugs; 2000 Feb; 18(1):7-16. PubMed ID: 10830137
[TBL] [Abstract][Full Text] [Related]
3. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
5. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
[TBL] [Abstract][Full Text] [Related]
6. Early oncology clinical trial design in the era of molecular-targeted agents.
Brunetto AT; Kristeleit RS; de Bono JS
Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
[TBL] [Abstract][Full Text] [Related]
7. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
8. Newer phase II trial designs gaining ground.
Benowitz S
J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
[No Abstract] [Full Text] [Related]
9. Multinomial phase II trial designs.
Freidlin B; Dancey J; Korn EL; Zee B; Eisenhauer E
J Clin Oncol; 2002 Jan; 20(2):599. PubMed ID: 11786592
[No Abstract] [Full Text] [Related]
10. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
12. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.
Parulekar WR; Eisenhauer EA
J Natl Cancer Inst; 2004 Jul; 96(13):990-7. PubMed ID: 15240782
[TBL] [Abstract][Full Text] [Related]
14. Novel agents: clinical trial design.
Tan AR; Swain SM
Semin Oncol; 2001 Oct; 28(5 Suppl 16):148-53. PubMed ID: 11706406
[TBL] [Abstract][Full Text] [Related]
15. Practice and progress in kidney cancer: methodology for novel drug development.
Rini BI; Weinberg V; Small EJ
J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
[TBL] [Abstract][Full Text] [Related]
16. Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
Harrington JA; Hernandez-Guerrero TC; Basu B
Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):770-777. PubMed ID: 29108786
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
18. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
20. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
